

Recent advances in chemotherapy for pancreatic cancer recommendations in guidelines

Journal of Gastroenterology

55, 369-382

DOI: [10.1007/s00535-020-01666-y](https://doi.org/10.1007/s00535-020-01666-y)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Efficacy of EUS-guided FNB using a Franseen needle for tissue acquisition and microsatellite instability evaluation in unresectable pancreatic lesions. <i>BMC Cancer</i> , 2020, 20, 1094.	1.1	18
2	Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. , 2020, 8, e001367.		62
3	Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cells. <i>International Journal of Biological Sciences</i> , 2021, 17, 589-602.	2.6	37
4	A Review of the Research on Symptom Clusters in Cancer Survivors. <i>Open Journal of Nursing</i> , 2021, 11, 423-434.	0.2	2
5	Immunotherapy for pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 751-759.	0.8	18
6	Nuclear Factor Erythroid 2-Related Factor 2 Depletion Sensitizes Pancreatic Cancer Cells to Gemcitabine via Aldehyde Dehydrogenase 3a1 Repression. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 33-40.	1.3	10
7	Pancreatic cancer in 2021: What you need to know to win. <i>World Journal of Gastroenterology</i> , 2021, 27, 5851-5889.	1.4	59
8	Current status and future perspectives of clinical research in pancreatic cancer: Establishment of evidence by science. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 741-757.	1.4	4
9	The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4733.	1.7	13
10	SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2. <i>Cancer Science</i> , 2021, 112, 4987-4999.	1.7	22
11	Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. <i>World Journal of Clinical Cases</i> , 2020, 8, 2778-2786.	0.3	1
12	HIF-1 and NRF2; Key Molecules for Malignant Phenotypes of Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 411.	1.7	11
13	Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel. <i>PLoS ONE</i> , 2022, 17, e0264653.	1.1	5
14	Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210932.	0.4	0
15	Using Single Cell Transcriptomics to Elucidate the Myeloid Compartment in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
16	Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
17	Linderlactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signaling Pathway. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	1
18	Chemotherapy effectiveness and age-group analysis of older adult patients with metastatic pancreatic cancer: A Japanese cancer registry cohort study. <i>Journal of Geriatric Oncology</i> , 2022, 13, 1208-1215.	0.5	5

#	ARTICLE	IF	CITATIONS
19	KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
20	Single Cell RNA Sequencing: A New Frontier in Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 4589.	1.7	3
22	Advancements of Prussian blue-based nanoplatfoms in biomedical fields: Progress and perspectives. <i>Journal of Controlled Release</i> , 2022, 351, 752-778.	4.8	9
23	Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial. <i>Japanese Journal of Clinical Oncology</i> , 2023, 53, 130-137.	0.6	1
24	Transparency of clinical trials in pancreatic cancer: An analysis of availability of trial results from the ClinicalTrials.gov database. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
25	Multicenter comparative study of endoscopic ultrasound-guided fine-needle biopsy using a Franseen needle versus conventional endoscopic ultrasound-guided fine-needle aspiration to evaluate microsatellite instability in patients with unresectable pancreatic cancer. <i>Clinical Endoscopy</i> , 0, , .	0.6	0
26	Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
27	Unraveling the significance of exosomal circRNAs in cancer therapeutic resistance. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4